OKUR
OnKure·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OKUR
Onkure Therapeutics, Inc.
A clinical-stage pharmaceutical company focused on the treatment of rare genetic mitochondrial diseases
Biological Technology
09/22/2014
04/09/2021
NASDAQ Stock Exchange
46
12-31
Common stock
6707 Winchester Circle, #400, Boulder, Colorado 80301
--
OnKure Therapeutics, Inc., was incorporated in Delaware on September 22, 2014. OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines for bio-validation drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a strong pipeline of oncology agnostic drug candidates designed to achieve optimal efficacy and tolerability. OnKure is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead project. OnKure aims to be a leader in targeting carcinogenic PI3Kα and has several best-in-class targeting projects aimed at achieving this key oncogene.
Company Financials
EPS
OKUR has released its 2025 Q2 earnings. EPS was reported at -1.14, versus the expected -1.25, beating expectations. The chart below visualizes how OKUR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
